TCXpress™, a novel promising TCR platform
TCXpress™, a novel promising TCR platform Read More »
BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Office
Dr. Keefe to lead the product development and manufacturing of BlueSphere Bio’s first clinical candidate, a TCR T-cell therapy directed against the miHA HA-1. PITTSBURGH, PA, April 26, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and
BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Office Read More »
BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting
PITTSBURGH, PA, March 15, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., hematologist/oncologist at UPMC Hillman Cancer Center and Assistant Professor, Division of Hematology-Oncology and of Immunology
